Kornimate/medical-research-clean huggingface dataset:
bone marrow and blood samples from patients with metastatic choroid melanoma

Conditions: Intraocular Melanoma

Summary: rationale: studying samples of bone marrow and blood from patients with cancer may help doctors find out the extent of disease. purpose: this research study is collecting bone marrow and blood samples from patients with metastatic choroid melanoma.

objectives: primary * develop and validate a method of detecting tumor cells in the bone marrow and blood in patients with metastatic choroid melanoma. outline: while patients are under general anesthesia for standard treatment of their disease, samples of bone marrow from the iliac crest and blood are collected. samples are analyzed for the expression of tyrosinase and melan-a via rt-pcr.

Eligibility criteria:
disease characteristics: * choroid melanoma * metastatic disease * planning to undergo general anesthesia patient characteristics: * not pregnant or nursing * no contraindications to the collection of a bone marrow sample * no patient deprived of liberty or under trusteeship (including guardianship) * no social or psychological situations that preclude the ability to give consent prior concurrent therapy: * not specified

Keywords: metastatic intraocular melanoma ciliary body and choroid melanoma, medium/large size ciliary body and choroid melanoma, small size
prevention and treatment of patient before, during, and after covid-19 infection

Conditions: Covid19

Summary: anticov-220 prevents and treats before, during, and after infection with sars-cov-2. the composition is fractionally extracted from herbs, using flavonoids, isoflavonoids, and pregnenolone in combination with ascorbic acid as the key compounds in preventing and killing sars-cov-2; increase antibodies and protect cells; supplementing precursors to help the body strengthen antibodies and reduce the risk of infection; destroy spike protein, toxic protein, help prevent blood clots causing stroke; restore the physiological function of cells after virus infection; helps the body to stabilize the amount of cortisol in the blood as well as stabilize the production of specific antibodies. the composition participates in anti-inflammatory and cells protecting process, bringing blood cortisol, b-lymphocytes, cyfra 21-1, wbc, crp, fever, dyspnea, and other signs of respiratory tract inflammation to a normal state and normal limit.

anticov-220 can eliminate covid-19 and its variants at a very early stage when they have not had enough time to multiply and cause disease. anticov-220 contains precursors, flavonoids, special enzymes responsible for protecting human cell membranes and destroying cell membranes of some viruses, especially, covid-19 cannot replicate in the presence of anticov-220 in the body. anticov-220 contains precursors of cortisol. as the investigators know, cortisol has a cell anti-inflammatory, blood pressure regulation, blood sugar regulation, energy booster, and anti-stress role. it provides precursors to help direct and balance the amount of cortisol in the body that has been imbalanced before. anticov-220 contains flavonoids and isoflavonoids that are cytoprotective antioxidants, clinically proven to destroy sars-cov-2, hbv, hiv, hcv, viruses, reduce complications after covid-19 infection, prevent neurological sequelae, stroke, cardiovascular sequelae, respiratory sequelae, ... the anti-inflammatory, stress-reducing, cell-protective, anti-viral, and immunosuppressive process are performed by an in vivo method that has proven its effectiveness more than ten years ago. anticov-220 is an innovative product that can fight against covid-19 and its variants in the current epidemic situation. anticov-220 is committed to protecting the community of people infected with hbv, hiv, hcv, sars-cov-2 against the risk of the covid-19 pandemic and its mutations. anticov-220 easy to implement, highly effective, and helps reduce public health costs, which is essential in protecting human health. anticov-220 can be used alongside with current standard treatment regimens prescribed by the world health organization.

Eligibility criteria:
inclusion criteria: * all patients with underlying medical conditions who have been taking medications for these conditions. * patients with aids, hiv, hbv, hcv, and patients with co-infections. * the cancer patients are stable. * patients with congenital or acquired immunodeficiency. exclusion criteria: * unstable cancer patients.

Keywords: aids hiv hbv hcv stroke metabolic dissorder stress
study to evaluate the clinical efficacy and safety of tamsulosin alone or in combination with solifenacin for the treatment in men with lower urinary tract symptoms including overactive bladder symptoms

Conditions: Lower Urinary Tract Symptoms; Overactive Bladder; Benign Prostatic Hyperplasia (BPH)

Summary: the objective of this study is to evaluate the clinical efficacy and safety of tamsulosin alone or in combination with solifenacin for the treatment in men with lower urinary tract symptoms (luts) including overactive bladder (oab) symptoms in taiwan.


Eligibility criteria:
inclusion criteria: * clinical signs and symptoms of frequency and urgency related to benign prostatic hyperplasia for at least 3 months * i-pss(s) score of ≥ 12 * maximum flow rate (qmax) of 4 to15 ml/sec * mean urinary frequency of ≥ 8 micturitions per 24 hours and ≥ 1 episode of urgency per 24 hours as verified by the 3-day micturition diary * benign digital rectal examination (dre) result exclusion criteria: * clinically significant outflow obstruction * significant post void residue volume (pvr \>100ml) * prostate specific antigen (psa) ≥10 ng/ml * previous or planned prostate surgery, including transurethral resection of the prostate (turp) * transurethral microwave treatment (tumt), transurethral needle ablation (tuna), laser, or other invasive or minimally invasive procedures within 12 months * patient with a neurological cause for abnormal detrusor activity * patients with urinary tract infection, chronic inflammation, bladder stones, bladder neck, sclerosis, urethral stricture, prostatic cancer, severe vesical diverticulum * uncontrolled narrow angle glaucoma, urinary or gastric retention or any other medical condition which in the opinion of the investigator makes the use of anticholinergics contra-indicated * patients with any other complication which may cause voiding dysfunction * patients with severe hepatic dysfunction, severe renal dysfunction, severe cardiovascular disorder, orthostatic hypotension, or senile dementia * patients receiving any medication therapy for luts/bph 2 weeks prior to the study * use of drugs to treat incontinence currently * hypersensitivity to tamsulosin and/or solifenacin or to any component of the formulation * any clinically significant condition, which in the opinion of the investigator makes the patients unsuitable for the trial * patients had taken any investigational drug in the previous 3 months prior to this study

Keywords: tamsulosin solifenacin lower urinary tract symptoms overactive bladder
volume measurement and progression surveillance of intracerebral haemorrhage using transcranial ultrasound

Conditions: Stroke; Cerebral Hemorrhage

Summary: this study investigates the ability of ultrasound to measure the volume of a brain hemorrhage in the acute phase after hospital admission. it is known that approximately 30% of patients admitted with a brain hemorrhage will suffer from enlargement of the hematoma within the first hours after admission. in this study the investigators measure the volume of the hematoma every 30 minutes up to 6 hours after admission and every 2 hours between 6-12 hours.

this study investigates the use of transcranial ultrasound (tcu) for the surveillance of patients with intracerebral hemorrhages. using transcranial ultrasound makes it possible to visualize and follow the bleeding progression through 3 points of the scull where the bone is thin enough to allow the penetration of sound waves. this can be done at bedside. today the investigators do not know for sure if clinical parameters determine a haematoma expansion. tcu will allow us to follow the haematoma progression serially in the acute phase and relate the haematoma expansion to parameters like blood pressure, neurological status (nihss-score) and radiological signs of ongoing bleeding (spot signs) on ct-angiogram (cta). hypothesis: 1. bedside ultrasound volume assessment is accurate in estimating the haematoma volume compared to computer tomography (ct) and can dynamically document the haematoma expansion. 2. the haematoma expansion is accompanied by neurological deterioration and happens only with patients with ct demonstrated spot signs. 3. the haematoma expansion is observed with patients with high blood pressure. aim of study: 1. to validate the accuracy of ultrasound (us) compared to ct in estimating haematoma volume with ich patients. 2. to measure ich volume serially in the acute phase using us and up to 12 hours aiming at: * describing the timing of the haematoma expansion. * relating to neurological deterioration, systemic blood pressure and detection of spot signs on cta.

Eligibility criteria:
inclusion criteria: * patients admitted to bispebjerg hospital stroke unit with ct demonstrated spontaneous ich * hospital admission within 4,5 hours after symptom onset * cta on admission * gcs\>8 (non-comatose) exclusion criteria: * lack of informed consent * underlying pathology (tumor, avm, aneurism) * lack of temporal bone window

Keywords: transcranial ultrasound haematoma expansion
efficacy of fusidic acid 1% in the treatment of bacterial conjunctivitis

Conditions: Bacterial Conjunctivitis

Summary: the purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.


Eligibility criteria:
main inclusion criteria: * have a clinical diagnosis of suspected bacterial conjunctivitis in at least 1 eye, confirmed by the presence of purulent or mucopurulent ocular discharge and a grade ≥ 1 on the modified validated bulbar redness (vbr) conjunctival redness scale. * have not received any ocular treatment for conjunctivitis, aside from eyelid hygiene, ≤14 days prior to visit 1. * have a negative viral conjunctivitis test in both eyes. * agree to discontinue use of eye/eyelid cosmetics during study participation. * agree to discontinue use of contact lenses during study participation. * be willing and able to provide informed consent and comply with the study requirements. * not be currently pregnant or breastfeeding. if sexually active, agree to use approved contraception for the duration of the study. main exclusion criteria: * have signs and/or symptoms or a diagnosis of fungal, protozoal, or viral etiology ≤30 days prior to visit 1. * have experienced signs and symptoms of bacterial conjunctivitis for \>48 hours prior to visit 1. * require or are expected to require use of any non-study topical ocular medication or systemic medications prior to visit 1 as specified in the protocol as ineligible. * have any abnormality of the ocular anatomy or ocular disease/disorder specified in the protocol as ineligible. * have a known intolerance, sensitivity or allergy to the study medications or any of their components. * have participated in another clinical trial ≤30 days or received another experimental drug ≤90 days prior to visit 1. * have a family member or household member enrolled in this study. * have a condition which in the investigator's opinion may impact their safety or would negatively affect the conduct or outcome of the study. * be an employee of or immediate family member of an employee (directly related to study conduct) at the study site.

Keywords: conjunctival diseases eye diseases eye infections, bacterial bacterial infections infections eye infections conjunctivitis, bacterial conjunctivitis
repeated doses of misoprostol for medical treatment of missed miscarriage

Conditions: Missed Abortion

Summary: missed abortion is a condition where the fetus has perished but the miscarriage is not expelled. women often present at a routine ultrasound or with a slight brownish discharge. traditionally this condition has been treated with curettage or vacuum aspiration. lately, medical treatment has become more common due to less risk of infection and other complications. the routine medical treatment is 800mcg of misoprostol administered vaginally. we wish to examine of repeated doses of 400mcg misoprostol after the initial 800mcg vaginal misoprostol increases efficacy of the treatment.


Eligibility criteria:
inclusion criteria: * over 18 years of age healthy no contraindication to medical treatment visible fetal structures such as yolk sac or fetus exclusion criteria: * empty gestational sac more than sparse bleeding or dilated cervix mental instability after diagnosis contraindication to medical treatment

Keywords: missed abortion miscarriage
randomized controlled trial of chiropractic manipulation versus medical therapy for chronic neck pain

Conditions: Neck Pain

Summary: the purpose of this study is to determine whether chiropractic manipulation or medical therapy is effective in the treatment of chronic neck pain.

neck pain is a common complaint, approximately 10% of the population have neck pain. many modalities are used to treat neck pain, but no therapy has been found to be clearly superior. we conducted a randomized controlled study of chiropractic manipulation versus medical therapy for chronic neck pain. subjects (n=70) with neck pain for more than 3 months but with no evidence of radiculopathy or myelopathy were randomized. both groups were instructed to do neck exercises and use heat daily. the chiropractic group received 12 standardized manipulations over 6 weeks. nurses saw the medical group on the same visit schedule and received acetaminophen 1,000 milligrams four times a day as needed. blinded observer performed all measurements. the primary outcome measure was the neck disability index (ndi). secondary measures were pain via a visual analogue scale, global via medical outcome study short form and range of motion via cybex electronic inclinometer.

Eligibility criteria:
inclusion criteria: * neck pain for more than 3 months exclusion criteria: * cervical radiculopathy or myelopathy * contraindications to cervical manipulation: metastatic cancer, coagulation disorder, cervical spine abnormalities, neuromuscular disease * medical contraindications: uncontrolled hypertension, active coronary artery disease, history of cerebral vascular disease, alcohol or drug dependency, acetaminophen allergy * active litigation involving neck pain * medical or chiropractic treatment within the past 3 months

Keywords: neck pain chiropractic manipulation randomized controlled trial
evaluation of inflammation activity in ulcerative colitis by pcle

Conditions: Inflammation

Summary: the aim:1) to test the correlation of pcle-obtained features with histological findings in uc; comparing the real-time conventional colonoscopy baron score with cle assessment. 2) to test the accuracy of the investigators previously proposed simplified four-grade classification system of crypt architecture in evaluating inflammation activity in uc by pcle.

patients with acute inflammatory infiltrates seen on histological assessment are more likely to experience relapse than are those without infiltrates,studies suggest that severity of inflammation is a risk factor for colorectal neoplasia in uc. the assessment of inflammation activity by conventional colonoscopy is inaccurate in the prediction of acute inflammation in some cases. confocal laser endomicroscopy (cle) allows for real-time endoscopy and histological diagnosis of gastrointestinal diseases. in our previous study, we confirmed a simplified four-grade classification system of crypt architecture(grade a :normal; grade b: an irregular arrangement of colonic crypts with normal size and shape, and enlarged spaces between crypts; type c: an enlarged crypt opening and a more irregular crypt arrangement than type b; type d: crypt destruction and / or crypt abscess) by ecle in predicting acute inflammation, and found a good correlation with histology. in this study, the investigators aimed to test the accuracy of the proposed tne four-grade classification system in evaluating inflammation activity in uc by pcle.

Eligibility criteria:
inclusion criteria: * male or female aged 18-80; * patients previously or in-process diagnosed as ulcerative colitis exclusion criteria: * patients with gastrectomy, acute gi bleeding, and advanced esophageal cancer; * patients under conditions unsuitable for performing cle including coagulopathy (prothrombin time \ 50 s), lactation, food retention, oesophageal stenosis, postoperative cases, leiomyoma, impaired renal function (creatinine level \>1.2 mg/dl), pregnancy or breastfeeding, and known allergy to fluorescein sodium; * inability to provide informed consent and other situations that could interfere with the examination protocol.

Keywords: ulcerative colitis probe-based confocal laser endoscopy inflammation activity histology
infant-maternal partnership and cognitive training study for preterm infants

Conditions: Child Development; Infant Development; Infant, Premature, Diseases

Summary: this study will test the hypothesis that in preterm infants a caregiver-implemented early developmental intervention (edi) using finger puppets to develop joint attention and encourage interactive communication with routine edi care including bookworm training compared with routine edi care including bookworm training alone will increase the ages and stages questionnaire® score at 12 months corrected age.


Eligibility criteria:
inclusion criteria: * inborn at uab, delivered at less than 34 weeks' gestation, 32-39 weeks' pma, off sedatives, and off invasive respiratory support. exclusion criteria: * a major malformation, a known syndrome, enrolled in a competing trial targeting neurodevelopmental outcomes as a primary outcome.
development and validation of a psn-ai prediction model

Conditions: Colorectal Cancer; Peritoneal Metastases

Summary: heterogeneity concerning survival in synchronous peritoneal metastasis from patients with colorectal cancer exists, thereby further classification is urgently required. this study aimed to validate a psn-ai model based on dna ploidy, stroma-tumor fraction, and nucleotyping (psn) for the prediction of survival of synchronous peritoneal metastasis from colorectal cancer.


Eligibility criteria:
inclusion criteria: * histological proof of synchronous peritoneal metastases of a nonappendiceal colorectal adenocarcinoma. * resectable disease determined by computed tomography (ct) and a peritoneal cancer index (pci) of ≤20 at diagnostic laparoscopy or laparotomy; * no evidence of systemic (e.g. liver, lung) colorectal metastases within three months prior to enrolment; * undergoing cytoreduction surgery for synchronous peritoneal metastasis from colorectal cancer. exclusion criteria: * combined with other types of malignant tumors.

Keywords: colorectal cancer synchronous peritoneal metastasis dna ploidy stroma-tumor fraction nucleotyping
leptospirosis care bundle study

Conditions: Leptospirosis

Summary: so in management of leptospirosis patients there really is no another approach to treatment. the importance of the problem was acknowledged by the researchers. as a result, this study was performed in order to the leptospirosis care bundle has been used, and has been proved that its use can reduce the risk of acute renal failure.


Eligibility criteria:
inclusion criteria: * age \> 18 years * suspicious leptospirosis including body temperature \> 38 celcius, severe myalgia, and exposure to reservoir hospital of flood water. * calf muscle tenderness * conjunctival suffusion * anuria or oliguria and/or proteinuria * jaundice * hemorrhagic manifestations (pulmonary and intestine) * meningeal irritation * nausea, vomiting, abdominal pain, diarrhea. * admitted in hospital exclusion criteria: * other infectious disease * pregnancy
specific cognitive remediation for schizophrenia

Conditions: Schizophrenia

Summary: rationale: cognitive deficits are a core feature in schizophrenia. conventional treatments (antipsychotic medication and psychological treatments) have limited effects so cognitive remediation programs were designed to alleviate the problems. interventions typically involve a variety of exercises in a paper and pencil or a computerized format with a growing number of specialized computer programs now being developed. however, many of these programs lack specificity which does not allow an individual's specific needs to be addressed. more targeted interventions might increase the effects of therapy so recos - cognitive remediation for schizophrenia - was developed to fit this gap. methods: this is a multicenter, randomized, controlled study comparing patients aged 18 to 45 years suffering from schizophrenia according to dsm-iv-tr. recos will be compared to an already validated program (crt). 220 patients will be randomized as follows : * arm 1 : recos (42 h) * arm 2 : crt (42 h) the recruitment is performed by psychiatrists in lyon, paris, clermont-de-l'oise, niort, bordeaux, ville-evrard and lausanne.


Eligibility criteria:
inclusion criteria: * men and women aged 18 to 45 years * french speaker or french schooling since 7 years * clinical stability * diagnosis of schizophrenia exclusion criteria: * visual or auditory disorder * history of neurological illness or trauma * alcohol or drug dependence * mental retardation

Keywords: cognitive rehabilitation schizophrenia
a clinical study of albumin-bound paclitaxel/granulocyte-based therapy for recurrent/metastatic breast cancer

Conditions: Breast Cancer

Summary: the goal of this clinical trial is to learn if albumin-bound paclitaxel/granulocyte drug can treat patients with recurrent/metastatic breast cancer. the main questions it aims to answer are: to verify the safety of albumin-bound paclitaxel/granulocyte drug in patients with recurrent/metastatic breast cancer. to evaluate the efficacy of albumin-bound paclitaxel/granulocyte drug in patients with recurrent/metastatic breast cancer. to detect the pharmacokinetic behavior of albumin-bound paclitaxel/granulocyte drug in patients with recurrent/metastatic breast cancer.

in this open, single-armed study, selected patients with recurrent/metastatic breast cancer confirmed by histopathology will be received albumin-bound paclitaxel/granulocyte-based therapy. the granulocyte will be separated by blood cell separator, and will be cultured in the gmp laboratory to make albumin-bound paclitaxel/granulocyte drug. then the drug will be infused intravenous into patients.

Eligibility criteria:
inclusion criteria: * female, aged ≥ 18 years old; obtain an informed consent form voluntarily signed by the patient themselves; recurrent/metastatic advanced breast cancer patients (refer to tnm standard); patients who have received standard first-line treatments and expected survival time ≥ 3 months; eocg score ≤ 2 and kps≥ 70 points; liver, kidney and bone marrow functions are basically normal; patients of childbearing age need to take appropriate protective measures before enrollment and after treatment 3 months. exclusion criteria: * individuals who have received other anti-tumor treatment within 4 weeks prior the enrollment; patients with history of allergy to paclitaxel, albumin naproxen, ibuprofen, trimethoprim and ampicillin; positive blood pregnancy test; patients who required anti coagulant therapy; patients with active infectious diseases or a history of bone marrow or organ transplantation